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Background: Using more than one psychotropic substance is accompanied with increased risks for 
psychiatric and physical disorders. Accordingly, deficits in basal cognitive functions have been 
consistently associated with polysubstance use (PSU), whereas little is known about potential 
impairments in more complex socio-cognitive skills, which are relevant for daily-life functioning. 
Therefore, we investigated the effects of toxicological validated stimulant PSU on social cognition 
under consideration of potential cumulative effects. 
Methods: We compared socio-cognitive performances of 47 individuals with stimulant PSU with 59 
matched stimulant-naïve controls using the Multifaceted Empathy Test (MET) and the Movie for the 
Assessment of Social Cognition (MASC). Additionally, social network size was assessed by the Social 
Network Questionnaire (SNQ). Hair and urine testing was employed to categorize three PSU 
subgroups (3, 4, and ≥5 substances used) and to ensure drug abstinence in controls. 
Results: Individuals with stimulant PSU showed lower emotional empathy (MET) and a smaller social 
network (SNQ) compared to controls (both with linear trends for increasing number of used 
substances: p<.05). In contrast, cognitive empathy (MET and MASC) was largely unaffected by PSU. 
Additional linear regression analyses within PSU individuals revealed number of used substances as 
the best predictor for inferior performance in emotional empathy (p<.01), while severity of the use 
of single substances or substance-classes did not show a significant impact. 
Conclusion: These findings demonstrate cumulative adverse effects of stimulant PSU on an 
important facet of socio-cognitive functioning. Therefore, emotional empathy deficits should be 
targeted in future interventions and rehabilitations for individuals with PSU. 
 
 





The use of more than one psychotropic substance, concurrently or consecutively, is termed 
polysubstance use (PSU) (EMCDDA, 2002; Meyerhoff, 2017). PSU was previously diagnosed according 
to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) by the use of at least three 
substances (excluding caffeine and nicotine) within the same 12-month period. However, this 
definition has recently been removed in the DSM-5 (American Psychiaric Association, 1994; American 
Psychiatric Association, 2013). 
Three main reasons for PSU are commonly reported: (1) it can induce cumulative or complementary 
effects, (2) it can compensate negative effects of other drugs, and (3) it can reflect the replacement 
of a drug by another drug due to low prices, availability, or fashion (EMCDDA, 2009; Preedy, 2016). 
While the frequency of monosubstance use is decreasing over the last years, PSU instead has 
become a serious and increasing public health concern with regard to psychological (e.g., depression 
or anxiety) and physiological illnesses accompanied by an increased risk of intoxication, injury, and 
death (Connor et al., 2014; Karjalainen et al., 2017; Martin, 2008). Accordingly, 38% of drug-related 
hospital emergency presentations in Europe were reported to be caused by PSU (EMCDDA, 2016). 
Recently, neurocognitive effects of PSU have been investigated intensively indicating an increased 
interest in this research field of substance use. The study by Schmidt et al. (2017) investigated 
neurocognitive functioning in individuals with PSU and alcohol use disorders (AUD). The PSU group 
revealed inferior performances in auditory-verbal memory and learning, inhibitory control of 
impulsivity, decision-making, and global cognition compared to AUD (Schmidt et al., 2017). This is in 
line with previous findings of behavioral and neuroimaging studies investigating cognition in 
individuals with PSU and reporting similar deficits in cognitive efficiency, attention, memory, and 
delayed discounting (Connor et al., 2014; Fernandez-Serrano et al., 2011; Moody et al., 2016; 
Pennington et al., 2015). 
Apart from consistently reported neurocognitive impairments of PSU, little is known about its socio-
cognitive sequelae. Social cognition includes prosocial and interpersonal behavior such as empathy 
and emotion recognition, which are crucial for daily-life interactions (Singer and Lamm, 2009; Walter, 
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2012). Empathy is a multidimensional construct subdivided in at least two components: 1) cognitive 
empathy is characterized by the ability to understand the feelings of others without necessarily 
experiencing them and involves perspective-taking, also called Theory-of-Mind (ToM), and emotion 
recognition; 2) emotional empathy means to subjectively experience the others’ feelings (Decety and 
Jackson, 2004; Eres et al., 2015; Walter, 2012). Deficits in empathy have been demonstrated in 
various psychiatric diseases such as autism (Blair, 2005; Dziobek et al., 2008), schizophrenia (Derntl 
et al., 2009), depression (Cusi et al., 2011), psychopathy (Blair, 2005; Pfabigan et al., 2015), and in 
individuals with substance use disorders (Quednow, 2017; Reay et al., 2006; Uekermann and Daum, 
2008). More specifically, alcohol dependence is associated with deficits in emotional empathy, 
emotion recognition, and humor processing (Kornreich et al., 2003; Maurage et al., 2015; Maurage et 
al., 2011; Mohagheghi et al., 2015; Uekermann et al., 2007). Studies with chronic methamphetamine 
users consistently demonstrated deficits in emotion recognition and ToM (Henry et al., 2009; Kim et 
al., 2011). Furthermore, previous studies of our group revealed deficits in emotion recognition, ToM, 
and emotional empathy in cocaine users, whereas non-medical methylphenidate users mainly 
showed impairments in cognitive empathy (Hulka et al., 2013; Maier et al., 2015; Preller et al., 2014). 
In contrast, chronic 3,4-methylenedioxymethamphetamine (MDMA) users showed superior cognitive 
empathy accompanied by unaffected emotional empathy (Wunderli et al., 2017b). Studies 
investigating opioid-related effects reported impairments in social perception in substituted patients 
(Kornreich et al., 2003; McDonald et al., 2013). Finally, neuroimaging and electrophysiological studies 
with chronic cannabis users revealed altered physiological response during task performances of 
ToM and empathy (Platt et al., 2010; Roser et al., 2012; Troup et al., 2016).  
Although PSU is clinically highly relevant, studies investigating social cognition in individuals with PSU 
are limited to date. The study by Ferrari et al. (2014) demonstrated reduced emotional empathy with 
preserved cognitive empathy in addicted PSU patients compared to controls using a subjective self-
rating scale of the empathy quotient . These effects were specifically pronounced for males with PSU. 
Furthermore, deficits in recognition of facial emotion expressions were reported for individuals with 
PSU using a computer-based Ekman Faces Test (Fernandez-Serrano et al., 2010; Verdejo-Garcia et al., 
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2007). Moreover, a recent neuroimaging review by Meyerhoff (2017) reported consistent findings in 
individuals with PSU regarding structural alterations in the orbitofrontal cortex (OFC) and anterior 
cingulate cortex (ACC), which are associated with ToM and empathy (Abu-Akel and Shamay-Tsoory, 
2011; Bernhardt and Singer, 2012; Fan et al., 2011). 
In sum, studies investigating socio-cognitive functioning in individuals with PSU mainly focused on 
emotion recognition or subjective self-rating scales for empathy. Therefore, our aim was to assess 
emotional and cognitive empathy with complex stimuli in situational contexts using performance 
tasks. Furthermore, only two-group analyses were conducted so far comparing polysubstance users 
with controls while disregarding cumulative effects of multiple substances. Based on the study by 
Witt et al. (2015) reporting decreased cognitive performance with an increased number of consumed 
antiepileptics, we created a 4-group design for our study (three PSU subgroups vs. healthy controls) 
in order to consider the number of used substances. Although studies investigating PSU differ with 
respect to their classifications, they all have in common that PSU was assessed by self-reports. 
Because it is well-known that self-reports in substance users are distorted by social desirability biases 
and memory alterations (Latkin et al., 2017; Magura and Kang, 1996; Quednow et al., 2006), a 
further innovative aspect of our study was to investigate an objectively validated PSU sample based 
on hair and urine toxicology analyses. Given that deficits of emotional empathy have been shown for 
a variety of single substance users as well as for PSU assessed only by self-reports, we hypothesized 
that an increased number of used substances goes along with decreased performances in emotional 
empathy accompanied by increased impairments in real-life social functioning reflected in a smaller 




2.1. Recruitment and participants  
Participants in our PSU and control groups were initially recruited and assessed for our previous 
cocaine (Zurich Cocaine Cognition Study, ZuCoSt
2
; Hulka, Preller, Vonmoos, et al., 2013; Preller, 
Hulka, Vonmoos, et al., 2014; Vonmoos, Hulka, Preller, et al., 2013) and MDMA studies (Wunderli et 
al., 2017a). The present PSU sample was composed of individuals who were excluded from these 
previous studies because of PSU. Participants were initially recruited through flyers in addiction 
centers and hospitals, advertisements in local newspapers, internet platforms, and word of mouth. 
All participants were tested at the Psychiatric Hospital of the University of Zurich, aged between 18 
and 60 years, had proficiency in German language, and showed no severe physical, neurological, and 
psychiatric disorders according to DSM-IV with exception of substance abuse/dependence, attention 
deficit hyperactivity disorder (ADHD), and history of depression for the PSU sample. Specific 
exclusion criteria for the control group were a positive urine or hair toxicology and a medium to high 
alcohol risk level (see 2.2.). All participants were asked to abstain from illegal substances for at least 
72 hours and from alcohol 24 hours prior to the measurement. The study was approved by the Ethic 
Committee of the Canton Zurich. All participants provided written informed consent and were 
compensated for their participation. 
 
2.2. PSU sample 
Referring to DSM-IV criteria, we defined PSU as the consumption of at least three psychotropic 
substances within the last six months, including alcohol as the only legal drug and excluding tobacco 
use. Objective data were used to get a precise and valid estimation of illegal drug use and to avoid 
social desirability in subjective questionnaires. According to the social desirability hypothesis, 
Harrison (1997) postulated that the validity of self-reported substance use decreases in relation to 
the increase in stigmatization of the substance that is used. Alcohol is a legal drug, which is socially 
recognized with low stigmatization compared to illegal substances. Therefore, alcohol was the only 
drug for which no objective validation was collected, as we believed that our subjective data of 
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alcohol use were less biased than illegal drug use (Del Boca and Darkes, 2003; Lintonen et al., 2004). 
Based on the World Health Organization (WHO, 2000), we defined three groups of alcoholic risk 
consumption levels for men and women respectively with low (1), medium (2), and high (3) risk 
alcohol consumption levels (Table S1a
1
). Low level of alcohol consumption was not considered for 
the number of used substances in the PSU subgroups. Chronic cannabis use was confirmed by urine 
analyses because participants were asked to abstain from illegal substances for at least 72 hours and 
the window of detection for THC in urine samples is up to more than three weeks in frequent 
cannabis users (Musshoff and Madea, 2006). Additional psychotropic substance use (e.g., cocaine, 
MDMA, amphetamines, opioids, ketamine, 2,5-dimethoxy-4-bromophenethylamine [2C-B]) was 
quantified by hair analyses (see also 2.4. below). For urine samples, delta-9-tetrahydrocannabinol 
(THC) concentrations of at least 50 ng/ml were considered positive (Methods S1
1
). Three equal 
groups in relation to the group size were calculated over all positive urine samples of initially 
recruited participants (n=60) to differentiate again between low (1), medium (2), and high (3) 
substance use (Table S1b
1
). The same procedure was performed with hair samples to differentiate 
between three levels of substance use severity for each illegal substance (see Methods S2
1
 & Table 
S1c
1
). The average of the normalized cocaine, MDMA, and amphetamine hair values was used to 
define the final cut-off values for low (1), medium (2), and severe (3) substance use (Table S1c
1
). 
Furthermore, a PSU severity index (PSUSI) over all substances was calculated by summarizing the 
severity levels low (1), medium (2), high (3) of used substances.
 
Because participants were initially recruited for our previous studies investigating cocaine and 
MDMA users, participants were excluded if they revealed consumption of less than three substances 
or high severity level (level 3) of only one single substance accompanied with low levels (level 1) of 
additional substances indicating a primary drug of choice. Our final sample comprised three 
subgroups of PSU using three (n=31), four (n=10), and five or more substances (n=6) and 59 controls 
(Fig. 1). The groups were carefully matched for age, verbal IQ, years of education, and tobacco use. 
                                                             
1 Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by 
entering doi: 
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Data from the healthy stimulant-naïve controls of the present study has already been published in 
previous papers including the ZuCoSt
2
 and MDMA study (Vonmoos et al., 2013; Wunderli et al., 
2017a). However, our PSU sample does not contain any cocaine user included in previous ZuCo
2
St 
publications (e.g., Vonmoos et al., 2013) but revealed an overlap of 42.6% with the MDMA polydrug 
sample reported in the study by Wunderli et al. (2017a). 
 
2.3. Clinical Assessment 
The Structured Clinical Interview for Axis-I DSM-IV disorders (SCID I) was conducted by trained 
psychologists. Furthermore, participants completed the DSM-IV self-rating questionnaire assessing 
Axis-II personality disorders (SCID II). Because cocaine use was previously associated with higher 
scores in antisocial and narcissistic personality disorder (PD) domains (Preller et al., 2014), Cluster B 
PD including antisocial, borderline, histrionic, and narcissistic PD was calculated. To control for 
potential mood or attention differences between groups, the Beck Depression Inventory (BDI) (Beck 
et al., 1961) and the Attention Deficit Hyperactivity Disorder (ADHD) self-rating scale (ADHD-SR) 
(Rösler et al., 2005) were conducted. Premorbid verbal IQ was estimated by the Mehrfachwahl-
Wortschatz-Intelligenztest (Lehrl, 1999), which is a standardized German vocabulary test. 
 
2.4. Substance assessment 
Substance use over the last six months was assessed by means of a structured and standardized 
interview for psychotropic drug consumption (Quednow et al., 2004). Additionally, illegal substance 
use over the last six months was examined by 6cm-hair samples, which were segmented into two 
3cm segments analyzed separately. The average concentration of both hair segments was calculated 
and used for the final analyses. Twenty individuals (34%) in the control group and 13 (28%) in the 
PSU group had only one hair segment due to insufficient hair length. In these cases only this single 
values were introduced in the analyses. Hair samples were taken from the posterior vertex region of 
the head to assess the concentration of 11 common drugs and their metabolites by liquid 
chromatography-tandem mass spectroscopy (LC-MS/MS). Additionally, urine analyses were 
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conducted by semi-quantitative enzyme multiplied immunoassays in order to assess cannabis use 
(see also Methods S1
2
). 
2.5. Socio-cognitive assessment 
2.5.1 MASC 
The Movie for Assessment of Social Cognition (MASC) is a 15-minute video-based task with the 
intention of assessing mental and emotional perspective-taking (ToM), which is a facet of cognitive 
empathy, with an ecological valid method (Dziobek et al., 2006). During the video, participants were 
asked about the characters’ feelings, thoughts, and intentions. Four response alternatives were 
presented with one correct answer and three distractors. 
2.5.2 MET 
The Multifaceted Empathy Test (MET) is a computer-based task comprising 40 pictures showing 
people in distinct positive and negative emotional situations (Dziobek et al., 2008). Based on the 
multidimensional construct of empathy, the MET distinguishes between emotional and cognitive 
empathy. Emotional empathy (EE) is subdivided into explicit emotional empathy (EEE) assessed by 
ratings of the participants’ empathic concern, and implicit emotional empathy (IEE) measured by 
ratings of the participants’ arousal on a 9-point Likert scale. Cognitive empathy (CE) was measured by 
presenting four response-alternatives from which the participant had to choose one emotion, which 
fits the best to the person’s mental state on the picture. 
Additionally, we constructed a global cognitive empathy domain score (CES) including z-transformed 
CE and MASC data based on means and standard deviations of the control group according to 
Wunderli et al. (2017b). 





Furthermore, participants’ social contacts were measured by the Social Network Size Questionnaire 
(SNQ, for details see Preller et al., 2014). The number of personal contacts during the previous four 
weeks in specific life areas (household, family, work or education, friends, neighbors, and others) 
were named and subsumed to the total network size. 
 
2.6. Statistical analysis 
Statistical analyses were performed by SPSS 23.0 for Mac. Frequency data were analyzed by means 
of Pearson’s χ2 test. To determine quantitative differences between groups, analyses of variance 
(ANOVA) and covariance (ANCOVA) with the four groups as fixed factor (three PSU subgroups and 
controls) were used to control for age and sex because of differences in sex distribution between our 
groups and associations with prosocial behavior (Beadle et al., 2015; Kret and De Gelder, 2012; Miller 
et al., 1991). Furthermore, the severity index of PSU (PSUSI) was introduced as an additional 
covariate for the MET and MASC due to differences of the PSUSI between the groups and because of 
putative association between severity of substance use and emotion recognition in individuals with 
PSU (Fernandez-Serrano et al., 2010). Sidak-corrected post hoc analyses and linear group contrasts 
for trend analysis were performed regarding the number of used substances. Multiple linear 
regression analyses (forced entry) were conducted to estimate potential single substance-class 
effects (alcohol, THC, stimulants, and empathogens, see 3.3.) on socio-cognitive functioning over all 
individuals with PSU (n=47). Further linear regression analyses within the PSU subgroups were used 
to determine potential associations of clinical and demographic variables on socio-cognitive 
functioning. Cohen’s d effect sizes were calculated by the means and pooled standard deviations of 
the four groups (Cohen, 1988). The confirmatory statistical comparisons were carried out on a 
significance level of p<.05 (two-tailed). 
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3. Results 
3.1. Demographic characteristics 
Because of our matching procedure, groups did not differ with regard to verbal IQ, years of 
education, age, and smoking behavior (Table 1). However, individuals using five or more substances 
showed a different sex distribution compared to the other PSU subgroups with more females than 
males in this group. Individuals with PSU scored higher than controls on the BDI and ADHD-SR sum 
scores as substance use disorder is commonly associated with depression and ADHD (Quello et al., 
2005; Zulauf et al., 2014). Furthermore, Cluster B PD was significantly higher in polysubstance users 
(p<.001) compared to controls but no linear trend was detectable (p=.158). Means of alcohol 
consumption in gram and substance concentrations in hair and urine samples are shown in Table 1. 
The distribution of substance use between PSU subgroups are shown in Figure 3. The most 
frequently used substances over all PSU subgroups were cocaine (83%), MDMA (76.6%), alcohol 
(57.4% moderate or high use, Figure S1a
3
), amphetamine (40.4%), and cannabis (36.2%; Figure S1b
3
). 
The most common substance combinations over all PSU subgroups were cocaine-MDMA-alcohol 
(29.8%) and cocaine-MDMA-amphetamine (25.5%). As intended, the control group showed only low 
levels of alcohol consumption and no objectively quantified illegal substance use. 
 
3.2. Socio-cognitive functioning 
3.2.1. MASC 
An ANCOVA corrected for age, sex, and PSUSI with the dependent variable ToM correct sum score 
revealed no differences between the four groups and no linear trend (Table 2). Additional linear 
regression analysis including demographic and clinical variables as predictors revealed age (β=-.39, 




3.2.2. MET & CES 
                                                             
3 Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by 
entering doi: 
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ANCOVAs were performed for the dependent variables CE, EE, EEE, IEE, and CES with the fixed factor 
groups (Table 2). The results revealed differences between groups in EE (p<.05) with a significant 
linear trend (p<.05) showing decreased empathy scores with an increased number of used 
substances (Figure 2). No differences were found for CE and the global cognitive empathy score CES. 
Sidak-corrected pairwise comparison for emotional empathy revealed significant differences 
between individuals using three and four and three and five substances (Table 2). Cohen’s d yielded 
substantial differences in EEE, IEE, and EE mainly for individuals using more than three substances 
compared to controls and compared to individuals using three substances (Figure 4). Additional 







3.2.3. Social Network 
ANCOVA corrected for sex and age was conducted for analyzing differences of social contacts 
between the four groups. Results revealed a significant group effect and a linear trend (p<.05) with 
the smallest social network size in individuals using five or more substances (Table 2). Although 
Sidak-corrected pairwise comparisons revealed no significant differences between groups, the effect 
size between individuals using five or more substances and controls was very large (d=1.01) 
regarding social network size (Figure 4). Given that the reduced network sizes of the PSU groups 
might have been biased by unemployment status (i.e., less social contacts in work-related areas), we 
conducted an additional ANCOVA with employment status as a covariate. However, the main effects 
remained significant even after controlling for the employment status (group: F(1,98)=2.89, p=.039, 
linear contrast: p=.034). Furthermore, linear regression analysis including demographic and clinical 
variables as predictors revealed age as the only significant predictor (β=-.36, t=-2.07, p<.05) for social 




                                                             
4 Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by 
entering doi: 
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3.3. Regression models 
In order to find potential substance-class predictors for socio-cognitive functioning, we used multiple 
regression models (forced entry) within the PSU group (n=47, Table S3
5
). Model 1 concerned the 
estimation for the effects of single substance-class parameters, number of used substances, and 
PSUSI on EE. In the first step, dummy coded variables with the most frequently used substances 
separated for their neurochemical classes were included to estimate the effects of single substances 
independently. Therefore, we built four dummy coded substance-classes of alcohol use (n=27), THC 
use (n=17), stimulant use (n=45; cocaine, amphetamine, methamphetamine, and methylphenidate), 
and empathogen use (n=36, MDMA and 2C-B). Due to an insufficient number of ketamine (n=6) and 
opioid (n=4) users, we did not include these substances in the model. In a second step, we 
additionally introduced the number of used substance and in a third step the variable PSUSI. The 
analysis revealed no significance for any substance-class parameter (Table S3
5
). The number of used 
substances was the only significant predictor for EE (β=-.47, t=-3.04, p<.01; Model 1). Analogously, 
the same regression analysis was conducted with the dependent variable SNQ (Model 2). The 
dummy coded THC substance-class revealed statistical significance for social network size (β=.33, 
t=2.08, p<.05) showing more social contacts (M=19.12, SD=6.6) than stimulant (M=16.33, SD=6.8), 
empathogen (M=16.61, SD=6.6), and alcohol users (M=16.44, SD=7.3). 
  
                                                             




The innovative purpose of this study was to investigate socio-cognitive functioning in objectively 
validated stimulant polysubstance users and considering the number of used substances as well as 
severity of PSU. Our results revealed decreased performance in emotional empathy and fewer social 
contacts with an increased number of used substances. However, cognitive empathy was largely 
unaffected by PSU. Additionally, neither overall severity of PSU (PSUSI) nor single substance-classes 
revealed an impact on emotional empathy. In sum, these results indicate that individuals with PSU 
show distinct deficits in socio-cognitive functioning, which are worsening with the number of used 
substances. 
Our results with regard to the performance task MET are consistent with the study by Ferrari et al. 
(2014) demonstrating self-reported deficits in emotional empathy but not in cognitive empathy in 
individuals with PSU. Furthermore, the authors reported sex differences revealing deficits of 
cognitive empathy only in women and stronger deficits of emotional empathy and the total empathy 
score in men. However, our statistical analyses did not detect a significant interaction of sex and PSU 
on EE. The present results are also in accordance with previous neuroimaging findings in individuals 
with PSU reporting grey matter atrophy found in regions associated with emotional empathy such as 
the ACC (Fan et al., 2011), while no structural differences between individuals with PSU and alcohol 
users were reported (Meyerhoff, 2017). We found similar deficits in emotional empathy related to 
stimulant PSU as shown for alcohol dependent individuals (Maurage et al., 2011; Mohagheghi et al., 
2015) and also for pure cocaine users (Preller et al., 2014). Furthermore, the global cognitive 
empathy score (CES) remained unaffected by PSU. Therefore, we could not replicate the findings by 
Fernandez-Serrano et al. (2010) and Verdejo-Garcia et al. (2007), reporting deficits in emotion 
recognition, which is one important facet of cognitive empathy. However, crucial differences 
compared to our study sample exist. First, their PSU group was defined by self-reports, whereas our 
sample was objectively validated by hair and urine toxicology because self-reported substance use is 
often biased by distorted memories or social desirability (Harrison, 1997; Latkin et al., 2017; Magura 
and Kang, 1996; Quednow et al., 2006). Secondly, only two-group comparisons were conducted 
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disregarding the number of used substances. Moreover, Fernandez-Serrano et al. (2010) and 
Verdejo-Garcia et al. (2007) used the Ekman Faces Test assessing only emotion recognition in faces, 
whereas the MET used in our study measures emotion recognition in complex emotionally laden 
scenes likely engaging processes integrating different pathways of emotion recognition. Finally, our 
PSU group showed much less opioid consumption compared to the other study samples because 
opioid use was an exclusion criterion in the previous studies from which we created our PSU group. 
Given that we created the PSU sample out of excluded participants initially recruited for cocaine or 
MDMA use, we additionally analyzed the effects of stimulants, empathogens, THC, and alcohol on 
socio-cognitive functioning. However, no single substance-class indicator was identified for EE and 
CES. One possible reason for this could be that impairments in individuals with PSU rather resulted 
from opposing effects of different substances than from one single substance. Accordingly, findings 
of our previous studies using also the MET and MASC revealed deficits of emotional and cognitive 
empathy in relatively pure cocaine users, whereas MDMA use was associated with superior cognitive 
empathy (Preller et al., 2014; Wunderli et al., 2017b). Although we excluded individuals showing one 
primary drug, cocaine and MDMA were the most frequently used substances and the most common 
combination in our PSU sample. Therefore, our findings might result from the opposing effect of both 
substances and additional substance use. Furthermore, individuals showing more deficits in sharing 
other’s feelings might be prone to use more substances, which leads to the discussion of the cause-
effect relationship. 
Although severity of substance use in individuals with PSU was discussed as a potential predictor for 
emotion recognition deficits in the study by Fernandez-Serrano et al. (2010), our severity index of 
PSU (PSUSI) revealed no association with socio-cognitive functioning. However, the authors reported 
that specifically lifetime quantity of cocaine use was associated with socio-cognitive deficits, which 
was assessed by self-reports. In contrast, the PSUSI of our study was an estimation of severity of use 
over all substances. Therefore, our results might indicate that reported deficits of PSU were rather 
driven by the number of used substances than by the summed severity of use of all substances. 
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Our findings demonstrate that individuals using five or more substances revealed the fewest social 
contacts. Moreover, cannabis users showed a larger social network than stimulant, empathogen, and 
moderate to heavy alcohol users. Again, this finding could be discussed by a cause-effect relationship 
regarding PSU and deficits in emotional empathy. Chronic PSU might induce impairments in 
experiencing other’s feelings resulting in blunted emotional responses in given situations, which 
could lead to increased interpersonal conflicts and therefore to decreased social contacts. Moreover, 
decreased social contacts might be compensated by an increased use of additional substances. 
Alternatively, deficits in emotional empathy might reflect a predispositional trait (e.g., an antisocial 
or psychopathic personality) causing both, a decreased social network and PSU. Analysis of the SCID-
II Cluster B revealed higher scores for individuals with PSU without a linear trend indicating a general 
antisocial and psychopathic behavior in substance users independently from the number of used 
substances. Similar results were also found in pure cocaine users (Preller et al., 2014). Furthermore, 
individuals with psychopathic PD showed similar deficits in emotional empathy as in our PSU sample 
(Blair, 2005) suggesting that PSU might facilitate psychopathic behavior or that individuals with 
psychopathic traits might tend to show PSU.  
Our results indicate that individuals with PSU show preserved cognitive empathy suggesting that the 
ability of interpreting and recognizing emotions of others’ as well as mentalizing behaviors were 
largely unaffected by PSU. However, the ability of subjectively sharing others’ emotions was impaired 
in the PSU subgroups compared to controls, which is important for building meaningful interpersonal 
relationships and prosocial behavior (Singer and Lamm, 2009). Impaired emotional empathy can lead 
to severe deficits in daily life interactions especially in social relationships. Therefore, our results 
indicate a stronger implication of emotional empathy in the intervention and rehabilitation of PSU. 
Improving emotional empathy in specific intervention programs could ameliorate interpersonal 
communication in daily life situations and within social relationships but also during psychotherapy. 
Accordingly, individuals with PSU would receive a broader support of their social network, which in 
turn prevents relapse and facilitate a positive therapy outcome (Atadokht et al., 2015; Ellis et al., 
2004; Havassy et al., 1991). 
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This study shows some limitations. First, our PSU sample was dominated by individuals using 
stimulants whereas opioid use was less present compared to other PSU studies (Fernandez-Serrano 
et al., 2010; Ferrari et al., 2014; Verdejo-Garcia et al., 2007). This is based on the fact that we created 
the sample out of former excluded participants from the ZuCoSt
2 
and MDMA study where opioid use 
was and exclusion criterion (Hulka et al., 2013; Preller et al., 2014; Vonmoos et al., 2013; Wunderli et 
al., 2017a). Additionally, we could not include opioids and ketamine as dummy coded variables in the 
regression model due to small sample sizes. Furthermore, we were not able to use hair 
concentration as a variable in our regression model because they were not normally distributed even 
after log-transformation. Therefore, the substance-use variables were dichotomized. Secondly, the 
sample size for the groups using four or five substances was relatively small. Therefore, post-hoc 
tests mostly did not reveal significant differences between PSU subgroups. However, effect sizes 
showed considerable differences in social contacts and emotional empathy for the subgroups. Third, 
pre-existing differences and predispositions cannot be fully excluded due to our cross-sectional 
design. As mentioned before, no final cause statement can be done. Future studies should address 
this limitation conducting longitudinal studies with PSU and adding more specific instruments for 
psychopathic or antisocial personality traits. 
Taken together, our findings indicate that individuals with stimulant PSU show discrete impairments 
in emotional empathy with unaffected cognitive empathy. The innovative aspect of the present study 
was to investigate socio-cognitive functioning in an objectively validated PSU sample and to assess 
cumulative effects by the number of used substances. Our results indicate a gradual decrease of 
social contacts and performances in emotional empathy related to an increased number of used 
substances. However, the ability of emotion recognition, metalizing behavior, and perspective-taking 
was preserved. Taken together, our results suggest a stronger focus on emotional empathy in 
psychotherapeutic settings for future interventions and rehabilitations in PSU. 
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Table 1: Demographic, clinical, and substance use data (means and standard deviations) 
  Controls 3 substances 4 substances 5 substances value df p 
  (n=59) (n=31) (n=10) (n=6)       
Female/male 16/43 6/25 4/6 5/1 χ2 = 10.64 3 0.014 
Age 30.98 (9.3) 29.90 (8.9) 29.6 (7.6) 24.33 (4.0) F = 1.05 3, 102 0.372 
Years of education 10.51 (1.8) 10.32 (1.7) 10.10 (1.7) 11.00 (1.7) F = 0.41 3, 102 0.744 
Verbal IQ 105.34 (10.0) 103.03 (11.5) 104.9 (12.5) 100.83 (5.9) F = 0.57 3, 102 0.637 
Employment yes/no 50/9 23/8 8/2 4/2 χ2 = 2.16 3 0.539 
BDI sum score 3.66 (4.0) 7.39 (5.5)* 7.8 (10.2) 10.17 (11.3) F = 4.91 3, 102 0.003 
ADHD-SR 6.36 (4.2) 15.10 (9.3)** 12.2 (6.1) 15.5 (16.4)* F = 11.61 3, 102 <0.001 
SCID II 
      Cluster B 18.35 (12.6) 30.80 (15.1)** 31.09 (9.8)* 26.72 (16.3) F = 7.06 3,100 <0.001 
Smoker y/n  44/15 28/3 9/1 6/0 χ2 = 5.43 3 0.143 
Cigarettes/week 
(only smokers) 
73.24 (64.7) 93.08 (67.4) 138.44 (75.5)* 92.38 (30.9) F = 2.61 3, 83 0.057 
Alcohol g/week
a 
76.88 (59.8) 260.38 (263.3)** 298.10 (102.0)** 234.67 (145.9) F = 19.25
b 
3, 15.4 <0.001 










 (%) 0(0%) 15 (48.4%) 8 (80%) 4 (66.7%) 
Gram/week 426.52 (292.8) 311.08 (110.0) 295.00 (143.1) 
THC 
HP pos (%) 0(0%) 12 (38.7%) 3 (30%) 2 (33.3%) 
UP ng/ml (50)
d 
0.0 117.58 (126.8) 99.00 (33.8) 218.50 (188.8) 
Cocaine 
HP pos (%) 0(0%) 25 (80.6%) 8 (80%) 6 (100%) 
HP ng/mg (0.5)
d
 0.0 7.45 (8.12) 22.08 (44.3) 9.29 (13.7) 
MDMA 
HP pos (%) 0(0%) 22 (71%) 8 (80%) 6 (100%) 
HP ng/mg (0.2)
d
 0.0 6.46 (11.6) 4.23 (7.1) 8.12 (12.3) 
Amphetamine 
HP pos (%) 0(0%) 7 (22.6%) 7 (70%) 5 (83.3%) 
HP ng/mg (0.2)
d
 0.0 0.58 (0.6) 0.79 (0.6) 5.73 (6.9) 
Methamphetamine 
HP pos (%) 0(0%) 0 (0%) 1 (10%) 1 (16.7%) 
HP ng/mg (0.2)
d
 0.0 0.0 0.73 (0.0) 0.49 (0.0) 
Methylphenidate 
HP pos (%) 0(0%) 6 (19.4%) 1 (10%) 0 (0%) 
HP ng/mg (0.02)
d
 0.0 0.12 (0.1) 0.07 (0.0) 0.0 
Ketamine 
HP pos (%) 0(0%) 2 (6.5%) 1 (10%) 3 (50%) 
HP ng/mg (0.1)
d
 0.0 0.42 (0.1) 0.38 (0.0) 0.35 (0.4) 
2C-B 
HP pos (%) 0(0%) 1 (3.2%) 1 (10%) 1 (16.7%) 
HP ng/mg (0.1)
d
 0.0 0.09 (0.0) 0.11 (0.0) 0.13 (0.0) 
Morphine 
HP pos (%) 0(0%) 0 (0%) 1 (10%) 1 (16.7%) 
HP ng/mg (0.2)
d
 0.0 0.0 0.20 (0.0) 1.75 (0.0) 
Codeine 
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HP pos (%) 0(0%) 0 (0%) 1 (10%) 1 (16.7%) 
HP ng/mg (0.2)
d
 0.0 0.0 0.93 (0.0) 0.55 (0.0) 
Tramadol 
HP pos (%) 0(0%) 2 (6.5%) 0 (0%) 0 (0%) 
HP ng/mg (0.2)
d
 0.0 4.68 (6.1) 0.0 0.0 
Methadone 
HP pos (%) 0(0%) 1 (3.2%) 0 (0%) 0 (0%) 
HP ng/mg (0.2)
d
 0.0 1.15 (0.0) 0.0 0.0       
Note. ANOVAs and Chi
2
 for frequency distribution (two-tailed). Significant p-values (p<.05) are shown in bold.  
Data for Cluster B PD was missing for two participants of the control group. Substance data reported for participants with 
positive substance values. 
* Indicates Sidak post hoc p<.05 vs. controls, ** p<.01 vs controls. ° Indicates Sidak post hoc p<.05 vs. 3 substances used, °° 
p<.01 vs. 3 substances used. 
+ 
Indicates Sidak post hoc p<.05 vs. 4 substances used, 
++
p<.01 vs. 4 substances used. 
^
Indicates Sidak post hoc p<.05 vs. 5 substances used, 
^^
 p<.01 vs. 5 substances used. 
ADHD: attention-deficit/hyperactivity disorder, BDI: Beck's Depression Inventory, PSUSI: polysubstance use severity index 
a
 Alcohol use over all participants 
b
 Welch test 
c 
WHO definition (2000) 
d
 Cut-off values 
 
 
Table 2: Results of socio-cognitive functioning (mean and SE) 
controls 3 substances 4 substances 5 substances F df, df p 
p linear 
contrast 








Cognitive empathy CE 24.10 (1.4) 24.58 (1.4) 25.82 (2.4) 25.43 (3.5) 0.19 3, 99 0.905 0.722 
Emotional empathy EE 5.42 (0.5) 4.86 (0.5) 3.30 (0.8)* 2.60 (1.2) 3.64 3, 99 0.015 0.049 
     EEE 5.61 (0.5) 5.13 (0.5) 3.38 (0.8)* 2.80 (1.1)* 4.58 3, 99 0.005 0.040 








Social contacts 19.75 (0.8) 16.70 (1.1) 17.17 (1.9)  13.17 (2.6) 3.13 3, 99 0.029 0.029 




 Data for one participant of the control group was missing. 
* Indicates Sidak post hoc p<.05 vs. 3 substances used. 
EEE: explicit emotional empathy, IEE: implicit emotional empathy, PSUSI: polysubstance use severity index, SNQ: social 
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Highlights (3-5 highlights; max 85 characters including spaces per bullet point) 
 
 Investigation of cumulative effects of polysubstance use on socio-cognitive function. 
 Objectively validated group classification defined by hair and urine toxicology. 
 Decreased emotional empathy was associated with increased number of used substances. 
 Increased number of used substances was accompanied with fewer social contacts. 
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Fig. 1. Flow diagram of the final study sample.  








Fig. 2. Means and standard errors of emotional empathy (EE) and its subscales explicit 
emotion empathy (EEE) and implicit emotional empathy (IEE) of the MET. 












































Fig. 3. Distribution of substance use over all positive hair concentrations between PSU 
subgroups. 







Fig. 4. Cohen’s d effect sizes for comparisons between controls and PSU subgroups. 
Note. EE: emotional empathy, EEE: explicit emotional empathy, IEE: implicit emotional 


























































































Table S2:  Linear  regression  analyses  for  clinical  and  demographic  variables  predicting 
socio‐cognitive functioning 








Urine  toxicology analyses  included  following substances with cut‐off values  in parentheses 
(Substance  Abuse  and  Mental  Health  Services  Administration,  2012):  amphetamine 
(<300ng/ml),  benzodiazepine  (<200ng/ml),  tetrahydrocannabinol  (<50ng/ml),  cocaine 




were  collected  (if  possible)  and  analyzed  with  liquid  chromatography‐tandem  mass 
spectrometry  (LC‐MS/MS).  Proximal  hair  segments  with  a  length  of  up  to  six  cm  were 









grade)  in water. As  internal  standards  deuterated  standards  of  the  following  compounds 
were  used,  added  as  mixture  of  the  following  compounds:  cocaine‐d3,  morphine‐d3, 
codeine‐d3,  amphetamine‐d6,  methamphetamine‐d9,  MDMA‐d5,  methadone‐d9, 
methylphenidate‐d9,  tramadol‐d3.  All  deuterated  standards  were  from  ReseaChem 
(Burgdorf, Switzerland), the solvents for washing and extraction were of analysis grade and 
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obtained  from Merck  (Darmstadt,  Germany);  LC‐solvents  were  of  HPLC  grade  and  were 
obtained from Sigma Aldrich (Buchs, Switzerland). 
The LC‐MS/MS apparatus was an ABSciex QTrap 3200 (Analyst software Version 1.5, Turbo V 




Shimadzu  CTO  20 AC  column  oven,  Shimadzu, Duisburg, Germany). Gradient  elution was 










substances  [i.e.,  cocaine  (n=111), MDMA  (n=78),  and  amphetamine  (n=27)] were used  to 
calculate separation values for three equal groups  in relation to the group size.  In order to 
be  able  to  compare  values  of  different  hair  samples,  we  normalized  them  by  dividing 
substance hair‐concentrations by  their cut‐off values  (Cooper et al., 2012). The average of 
the normalized cut‐off values in the three equal groups were used for the final classification 













































     (1) low  0.5 ‐ 1.87   1 ‐ 3.7  0.2 ‐ 0.36   1 ‐ 1.8  0.2 ‐ 0.86   1 ‐ 4.3   1 ‐ 3.3a 
     (1) medium  1.88 ‐ 6.62   3.8 ‐ 13.2  0.37 ‐ 0.74   1.9 ‐ 3.7  0.87 ‐ 3.54   4.4 ‐ 17.7   3.4 ‐ 11.5 








   B  SE B  β  T‐value  p 
Constant  32.020  7.590  4.217  0.000 
Sex  ‐0.415  1.385  ‐0.046  ‐0.300  0.766 
Age  ‐0.199  0.083  ‐0.389  ‐2.392  0.022 
YoE  ‐0.112  0.421  ‐0.041  ‐0.265  0.792 
Verbal IQ  0.113  0.063  0.298  1.814  0.078 
BDI sum score  ‐0.122  0.114  ‐0.215  ‐1.070  0.291 
ADHD‐SR  ‐0.058  0.082  ‐0.135  ‐0.709  0.483 








           
b) EE 
   B  SE B  β  T‐value  p 
Constant  3.561  2.732  1.303  0.200 
Sex  ‐0.322  0.498  ‐0.108  ‐0.647  0.522 
Age  0.030  0.030  0.178  1.011  0.318 
YoE  0.183  0.152  0.204  1.209  0.234 
Verbal IQ  ‐0.010  0.023  ‐0.082  ‐0.461  0.647 
BDI sum score  ‐0.021  0.041  ‐0.109  ‐0.502  0.618 
ADHD‐SR  ‐0.025  0.030  ‐0.178  ‐0.862  0.394 














   B  SE B  β  T‐value  p 
Constant  0.054  1.135  0.048  0.962 
Sex  ‐0.324  0.207  ‐0.239  ‐1.564  0.126 
Age  ‐0.019  0.012  ‐0.240  ‐1.493  0.144 
YoE  ‐0.016  0.063  ‐0.040  ‐0.258  0.798 
Verbal IQ  0.018  0.009  0.306  1.880  0.068 
BDI sum score  ‐0.025  0.017  ‐0.291  ‐1.464  0.151 
ADHD‐SR  0.001  0.012  0.018  0.098  0.923 








d) SNQ                
   B  SE B  β  T‐value  p 
Constant  16.328  12.891  1.267  0.213 
Sex  1.606  2.351  0.113  0.683  0.499 
Age  ‐0.292  0.141  ‐0.359  ‐2.070  0.045 
YoE  0.066  0.715  0.015  0.092  0.927 
Verbal IQ  0.085  0.106  0.140  0.801  0.428 
BDI sum score  ‐0.016  0.194  ‐0.018  ‐0.084  0.933 
ADHD‐SR  ‐0.069  0.139  ‐0.101  ‐0.497  0.622 















Model 1                      
   B  SE B  β  T‐value  p  R2 corr  p change in F 
Step 1  ‐0.076  0.945 
Constant  4.638  1.409  3.292  0.002 
Stimulants  0.056  1.118  0.008  0.050  0.960 
Empathogens  0.273  0.548  0.082  0.497  0.622 
THC  ‐0.236  0.489  ‐0.080  ‐0.482  0.632 
Alcohol  ‐0.123  0.479  ‐0.043  ‐0.256  0.799 
Step 2  0.100  0.004 
Constant  6.396  1.412  4.529  <0.001 
Stimulants  0.854  1.055  0.122  0.809  0.423 
Empathogens  0.788  0.529  0.236  1.489  0.144 
THC  ‐0.089  0.449  ‐0.030  ‐0.198  0.844 
Alcohol  0.319  0.462  0.111  0.690  0.494 
Number of used 
substances  ‐0.929  0.306  ‐0.466  ‐3.040  0.004 
Step 3  0.098  0.347 
Constant  5.981  1.479  4.043  <0.001 
Stimulants  1.149  1.101  0.164  1.044  0.303 
Empathogens  0.780  0.530  0.233  1.472  0.149 
THC  ‐0.061  0.451  ‐0.021  ‐0.135  0.893 
Alcohol  0.426  0.476  0.149  0.895  0.376 
Number of used 
substances  ‐1.231  0.441  ‐0.618  ‐2.791  0.008 









Model 2                      
   B  SE B  β  T‐value  p  R2 corr  p change in F 
Step 1  0.024  0.292 
Constant  15.686  6.316  2.483  0.017 
Stimulants  ‐2.695  5.009  ‐0.082  ‐0.538  0.593 
Empathogens  1.566  2.457  0.100  0.637  0.527 
THC  4.555  2.190  0.329  2.080  0.044 
Alcohol  0.970  2.149  0.072  0.452  0.654 
Step 2  0.013  0.472 
Constant  17.754  6.963  2.550  0.015 
Stimulants  ‐1.756  5.201  ‐0.053  ‐0.338  0.737 
Empathogens  2.172  2.609  0.138  0.833  0.410 
THC  4.727  2.215  0.341  2.134  0.039 
Alcohol  1.490  2.277  0.111  0.654  0.516 
Number of used 
substances  ‐1.093  1.507  ‐0.117  ‐0.725  0.472 
Step 3  ‐0.003  0.554 
Constant  16.463  7.344  2.242  0.031 
Stimulants  ‐0.838  5.464  ‐0.025  ‐0.153  0.879 
Empathogens  2.148  2.630  0.136  0.817  0.419 
THC  4.814  2.234  0.347  2.151  0.038 
Alcohol  1.824  2.362  0.135  0.772  0.445 
Number of used 
substances  ‐2.035  2.190  ‐0.217  ‐0.929  0.358 
PSUSI  0.470  0.788  0.132  0.597  0.554 
Note. Dependent variable: SNQ. Significant p‐values are shown in bold. 
Step 1: R2=.109 and F=1.28, p=.292. 
Step 2: R2=.120 and F=1.12, p=.364. 
Step 3: R2=.128 and F=.98, p=.452. 
The data met the assumption of independent errors (Durbin‐Watson value = 2.27) and collinearity (tolerance 
values > 0.7 and VIF > 1 & < 10)  
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Figure S1a: Distribution of alcohol use between PSU subgroups 
 
 
Figure S1b: Distribution of THC over all positive US between PSU subgroups 
 
Note. US: urine sample 
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